Terug
naar lijst
- Auteur
- Anthonie van der Wekken, Michel van den Heuvel
- Printdatum
- 21-06-2024
- E-pubdatum
- 20-06-2024
- Bron
- Medische Oncologie
Kunnen we rationele keuzes maken voor (chemo-)immuuntherapie bij NSCLC?
Inleiding Na jarenlange stilte is er met de komst van immuuntherapie in vroegstadium niet-kleincellig longcarcinoom (NSCLC) eindelijk belangrijke voortgang bereikt. … Verder lezen “Kunnen we rationele keuzes maken voor (chemo-)immuuntherapie bij NSCLC?”
- Goldstraw, P, et al. The IASLC Lung Cancer Staging Project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016;11(1):39-51.
- Gale, D., et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol 2022;33(5):500-10.
- Forde, P.M., et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386(21):1973-85.
- Felip, E., et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398(10308):1344-57.
- Wakelee, H., et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med 2023;389(6):491-503.
- Cascone, T., et al. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Ann Oncol 2023;34:s1295.
- Heymach, J.V., et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med 2023;389(18):1672-84.
- Antonia, S.J., et al. Overall survival with durvalumab after chemoradiotherapy in stage iii NSCLC. N Engl J Med 2018;379(24):2342-50.
- Spigel, D.R., et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022;40(12):1301 11.
- Sorin, M., et al. Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review and meta-analysis. JAMA Oncol 2024 Mar 21:e240057. doi: 10.1001/jamaoncol.2024.0057. Epub ahead of print. PMID: 38512301; PMCID: PMC10958389.